Effect of celecoxib on Ca2+ fluxes and proliferation in MDCK renal tubular cells

Journal of Receptors and Signal Transduction

Volumn 25, Issue 4-6, 2005, Pages 237-249

  Wang, J L ^a   Lin, K L ^a   Chen, W C ^b   Chou, C T ^c   Huang, C J ^d,e   Liu, C S ^b   Hsieh, C H ^b   Chang, C H ^b   Huang, J K ^a   Chang, H T ^a   Liu, S I ^a   Hsu, S S ^a   Jan, C R ^a,c  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^c Department of Medical Education and Research ^*  (Taiwan)

^d TIAN SHENG MEMORIAL HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Celecoxib; Cytotoxicity; Fura 2; MDCK; Renal tubular cells

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; CELECOXIB; THAPSIGARGIN; CALCIUM; FLUORESCENT DYE; PHOSPHOLIPASE C; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL PROLIFERATION; CELL VIABILITY; DOG; DRUG EFFECT; KIDNEY TUBULE CELL; NONHUMAN; ANIMAL; CELL LINE; CELL SURVIVAL; CYTOLOGY; KIDNEY TUBULE; METABOLISM;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; CALCIUM; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DOGS; FLUORESCENT DYES; KIDNEY TUBULES; PHOSPHOLIPASE C; PYRAZOLES; SULFONAMIDES;

EID: 30344441500     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890500464704     Document Type: Article

References (30)

1. De Leval X, Julemont F, Benoit V, Frederich M, Pirotte B, Dogne JM. First and second generations of COX-2 selective inhibitors. Mini Rev Med Chem 2004, 4, 597-601.
2. Stephens J, Laskin B, Pashos C, Pena B, Wong J. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology 2003, 42 (Suppl 3), iii40-iii52.
3. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: A potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev 2004, 28, 127-142.
4. Malhotra S, Shafiq N, Pandhi P. COX-2 inhibitors: A CLASS act or just VIGORously promoted. MedGenMed 2004, 6, 6.
5. Whelton A. COX-2-specific inhibitors and the kidney: Effect on hypertension and oedema. J Hypertens Suppl 2002, 20, S31-S35.
6. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999, 66, 76-84.
7. Bing RJ. Cyclooxygenase-2 inhibitors: Is there an association with coronary or renal events? Curr Atheroscler Rep 2003, 5, 114-117.
8. Giovanni G, Giovanni P. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol 2002, 15, 480-488.
9. Henao J, Hisamuddin I, Nzerue CM, Vasandani G, Hewan-Lowe K. Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 2002, 39, 1313-1317.
10. Bootman MD, Berridge MJ, Lipp P. Cooking with calcium: The recipes for composing global signals from elementary events. Cell 1993, 91, 367-373.
11. Brini M, Carafoli E. Calcium signalling: A historical account, recent developments and future perspectives. Cell Mol Life Sci 2000, 57, 354-370.
12. Clapham DE. Calcium signaling. Cell 1995, 80, 259-268.
13. 2+ movement and cell proliferation in human osteoblasts. Biochem Pharmacol 2004, 67, 1123-1130.
14. +-ATPases: A plausible link with its anti-tumor effect and cardiovascular risks. Biochem J 2002, 366 (Pt 3), 831-837.
15. Jan CR, Ho CM, Wu SN, Huang JK, Tseng CJ. Mechanism of lanthanum inhibition of extracellular ATP-evoked calcium mobilization in MDCK cells. Life Sci 1998, 62, 533-540.
16. 2+ mobilization in Madin Darby canine kidney cells. Eur J Pharmacol 1998, 355, 219-233.
17. 2+ increase and cytotoxicity in renal tubular cells. Life Sci 2004, 74, 2075-2083.
18. Hsu SS, Chen WC, Jiann BP, Chen JS, Huang JK, Chang HT, Cheng HH, Lo YK, Ho CM, Jan CR. Effect of the antidepressant maprotiline on calcium movement and the viability of renal tubular cells. Arch Toxicol 2004, 78, 453-459.
19. Putney JW Jr. A model for receptor-regulated calcium entry. Cell Calcium 1986, 7, 1-12.
20. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985, 260, 3440-3450.
21. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996, 19, 1518-1520.
22. Merritt JE, Jacob R, Hallam TJ. Use of manganese to discriminate between calcium influx and mobilization from internal stores in stimulated human neutrophils. J Biol Chem 1989, 264, 1522-1527.
23. 2+-ATPase. Proc Natl Acad Sci USA 1990, 87, 2466-2470.
24. Thompson AK, Mostafapour SP, Denlinger LC, Bleasdale JE, Fisher SK. The aminosteroid U73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. J Biol Chem 1991, 266, 23856-23862.
25. McFadzean I, Gibson A. The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. Br J Pharmacol 2002, 135, 1-13.
26. 2+ transport and beyond. J Physiol 2003, 557 (Pt 3), 729-740.
27. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 2002, 60, 6045-6051.
28. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004, 96, 1769-1780.
29. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004, 2, 632-642.
30. Stempak D, Gammon J, Klein J, Koren G, Baruchel S. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther 2002, 72, 490-497.